How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Breathing Disorders and Treatment Market
- By Disorder Type: Obstructive Sleep Apnea (OSA), Central Sleep Apnea (CSA), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Pulmonary Fibrosis
- By Treatment Type: Continuous Positive Airway Pressure (CPAP) Devices, Bi-level Positive Airway Pressure (BiPAP) Devices, Oral Appliances, Oxygen Therapy, Surgical Interventions, Pharmacological Treatments
- By End User: Hospitals, Sleep Clinics, Homecare Settings, Specialty Respiratory Clinics, Ambulatory Surgical Centers
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales, Third-Party Distributors
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Obstructive Sleep Apnea (OSA) leads By Disorder Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Breathing Disorders and Treatment Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Disorder Type 5
Treatment Type 6
End User 5
Distribution Channel 5
Companies profiled
ResMed Inc.
Philips Respironics (Royal Philips)
Fisher & Paykel Healthcare Corporation Limited
Invacare Corporation
Drive DeVilbiss Healthcare
Becton
Dickinson and Company (BD)
Medtronic plc
3B Medical Inc.
Vyaire Medical Inc.
Somnetics International Inc.
Curative Medical Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →ResMed Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Philips Respironics (Royal Philips)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fisher & Paykel Healthcare Corporation Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Invacare Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Drive DeVilbiss Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Medtronic plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →3B Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vyaire Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Somnetics International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Curative Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Apex Medical Corp.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →DeVilbiss Healthcare LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Natus Medical Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →CareFusion Corporation (BD)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,772M by 2033 · 9.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Obstructive Sleep Apnea (OSA)35.2
- Central Sleep Apnea (CSA)19.5
- Chronic Obstructive Pulmonary Disease (COPD)12.7
- Asthma15.7
- Pulmonary Fibrosis17.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,121M → $2,278M · 9.3%
Europe$781.4M → $1,698M · 10.2%
Asia Pacific$713.4M → $1,298M · 7.8%
Latin America$441.6M → $935.2M · 9.8%
Middle East and Africa$339.7M → $743.3M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.952026
8.962027
8.992028
9.002029
9.012030
9.032031
9.022032
9.042033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- ResMed Inc.18.1
- Philips Respironics (Royal Philips)12.9
- Fisher & Paykel Healthcare Corporation Limited8.4
- Invacare Corporation7.2
- Drive DeVilbiss Healthcare15.6
- Becton9.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Disorder Type41.9%
Treatment Type14.1%
End User16.9%
Distribution Channel27.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe24.4
- Asia Pacific18.7
- Latin America13.5
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| ResMed Inc. | 79 | 96 | 88 | 97 | 76 | 96 | 89 |
| Philips Respironics (Royal Philips) | 77 | 76 | 78 | 93 | 85 | 76 | 81 |
| Fisher & Paykel Healthcare Corporation Limited | 78 | 68 | 84 | 74 | 76 | 66 | 74 |
| Invacare Corporation | 66 | 77 | 80 | 75 | 58 | 75 | 72 |
| Drive DeVilbiss Healthcare | 72 | 68 | 67 | 75 | 74 | 77 | 72 |
| Becton | 65 | 50 | 61 | 60 | 54 | 71 | 60 |
| Dickinson and Company (BD) | 66 | 66 | 53 | 47 | 45 | 62 | 57 |
| Medtronic plc | 39 | 57 | 43 | 53 | 60 | 57 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- ResMed Inc.
- Philips Respironics (Royal Philips)
- Fisher & Paykel Healthcare Corporation Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| ResMed Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Philips Respironics (Royal Philips) | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Fisher & Paykel Healthcare Corporation Limited | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Invacare Corporation | − | ✓ | ✓ | ✓ | ◐ | ✓ |
| Drive DeVilbiss Healthcare | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Becton | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Dickinson and Company (BD) | ✓ | ◐ | ◐ | − | ◐ | ◐ |
| Medtronic plc | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1ResMed Inc.89
2Philips Respironics (Royal Philips)81
3Fisher & Paykel Healthcare Corporation Limited74
4Invacare Corporation72
5Drive DeVilbiss Healthcare72
6Becton60
7Dickinson and Company (BD)57
8Medtronic plc52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
ResMed Inc.Philips Respironics (Royal Philips)
Challenger3
Strong scale, closing on the leaders.
Fisher & Paykel Healthcare Corporation LimitedInvacare CorporationDrive DeVilbiss Healthcare
Contender2
Focused players with pockets of strength.
BectonDickinson and Company (BD)
Niche1
Specialists in a single segment or region.
Medtronic plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disorder Type in North America, then scale across Breathing Disorders and Treatment Market — a $196M beachhead inside a $2.97B market.
Beachhead (SOM)$196Mobtainable near-term
Serviceable (SAM)$1.18Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Obstructive Sleep Apnea (OSA)
Best fit — highest urgency & budget in Disorder Type.
Economic buyer79 fit
Central Sleep Apnea (CSA)
Strong fit — clear ROI and a fast path to value.
End user67 fit
Chronic Obstructive Pulmonary Disease (COPD)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disorder Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve18%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Disorder Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Breathing Disorders and Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation12%
Closed-won7%
$15.2KCAC
$79KLTV
5.2:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Breathing Disorders and Treatment Market is a durable-growth opportunity — $1.13B by 2033, compounding at 7.8%.
TAM · 2025$619Mtoday
TAM · 2033$1.13Bforecast
CAGR7.8%2027–2033
Cumulative$7.68Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.13BTotal addressable market
SAM$442MServiceable available market
SOM$85MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.8% CAGR
Demand compounds through 2033, outpacing GDP across Disorder Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disorder Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.13BLarge & growingTAM by 2033 at 7.8% CAGR
$442MServiceable nowreachable with today’s model
$85MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$883MBear5.1% CAGR
$1.13BBase7.8% CAGR
$1.45BBull10.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Breathing Disorders and Treatment Market — a $2.92B market by 2033. Plan: grow share from 8.5% to 13.4%.
Market size · 2033$2.92Btotal addressable
Market CAGR10.1%2027–2033
Target share13.4%from 8.5% today
Revenue ambition$391Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 13.4% | Behind |
| Revenue | $258M | $391M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 37.6% | 44.2% | Ahead |
| Customer retention | 88.7% | 95.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disorder Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disorder Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $46M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disorder Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Breathing Disorders and Treatment Market conversation — a $1.29B market you can size, segment and defend in minutes.
Market size · 2033$1.29Btotal opportunity
Growth3.6%CAGR to 2033
Addressable buyers1,492+accounts in scope
Typical ROI6.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disorder Type
Goal Grow share in Disorder Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.2×return on cost, year one
< 4 mopayback period
$47K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
ResMed Inc.Philips Respironics (Royal Philips)Fisher & Paykel Healthcare Corporation LimitedInvacare CorporationDrive DeVilbiss HealthcareBectonDickinson and Company (BD)Medtronic plc+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Breathing Disorders and Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Breathing Disorders and Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Breathing Filter Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBreathing Machine Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportBreathing Paper Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportBreathing Trainers Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBreeding Horses Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBrew and Beverage Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBrewed Beverages Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBrewer Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBrewing Machinery Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBrewing Products Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBRIC Advanced Wound Management Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBRIC Clinical Chemistry Market
Market size, share, segmentation and regional forecast.
$485M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.